How much funding has Disarm Therapeutics raised?

Disarm Therapeutics has raised $30.0M in total funding, most recently a Series A round.

Who are Disarm Therapeutics's investors?

Disarm Therapeutics's investors include Eli Lilly, Atlas Venture, Lightstone Ventures, AbbVie Ventures.

When was Disarm Therapeutics founded?

Disarm Therapeutics was founded in 2017.

Where is Disarm Therapeutics headquartered?

Disarm Therapeutics is headquartered in St. Louis, Missouri, United States.

What industry is Disarm Therapeutics in?

Disarm Therapeutics operates in Biotech, neurology.

How many employees does Disarm Therapeutics have?

Disarm Therapeutics has 11-50 employees.

Disarm Therapeutics

Acquired

St. Louis, United States · Founded 2017 · $30.0M raised

Biotech

neurology

Headquarters: St. Louis, Missouri
Employees: 11–50
Founded: 2017
Business Model: B2B

Website: disarmtx.com
Total Funding: $30.0M
Last Round: $30.0M Series ASep 2017
Rounds: 1

About

Disarm Therapeutics was a biotechnology company developing a new class of disease-modifying therapeutics that block SARM1 to prevent axonal degeneration, a pathological process common to many neurological diseases. Co-founded by Washington University scientists Aaron DiAntonio and Jeffrey Milbrandt, the company closed a $30 million Series A in 2017 and was acquired by Eli Lilly in October 2020, becoming a wholly-owned Lilly subsidiary focused on SARM1 inhibitor drug development.

Summary

Disarm Therapeutics is a Biotech company based in St. Louis, United States, founded in 2017. It has raised $30.0M in total across 1 round, most recently a $30.0M Series A round in Sep 2017. Investors include Eli Lilly, Atlas Venture and Lightstone Ventures.